CAJ | 학술논문

目的：探讨重组血管内皮抑素对晚期食管胃交接部腺癌患者外周血Treg、CD8＋T细胞、恶性肿瘤特异生长因子（ tumor specific growth factor，TSGF）的影响及临床疗效观察。方法收集唐山工人医院收治的晚期食管胃交接部腺癌患者52例，随机分为对照组和实验组，每组各26例，对照组给予OLF化疗方案，实验组给予OLF化疗方案联合重组血管内皮抑素治疗。每21 d为1个周期，共治疗4个周期。治疗结束后，对所有患者的外周血Treg、CD8＋T细胞水平、血清TSGF含量及临床疗效进行检测。结果治疗后，与对照组比较，实验组患者的外周血Treg水平较低（ P＜0．05）；外周血CD8＋T细胞水平较高（ P＜0．05）；血清TSGF含量较低（P＜0．05）；有效率较高（P＜0．05）。结论重组血管内皮抑素能够明显降低晚期食管胃交接部腺癌患者外周血Treg水平和血清TSGF含量，提高CD8＋T细胞水平，提高治疗的有效率，对临床有指导意义。
목적：탐토중조혈관내피억소대만기식관위교접부선암환자외주혈Treg、CD8＋T세포、악성종류특이생장인자（ tumor specific growth factor，TSGF）적영향급림상료효관찰。방법수집당산공인의원수치적만기식관위교접부선암환자52례，수궤분위대조조화실험조，매조각26례，대조조급여OLF화료방안，실험조급여OLF화료방안연합중조혈관내피억소치료。매21 d위1개주기，공치료4개주기。치료결속후，대소유환자적외주혈Treg、CD8＋T세포수평、혈청TSGF함량급림상료효진행검측。결과치료후，여대조조비교，실험조환자적외주혈Treg수평교저（ P＜0．05）；외주혈CD8＋T세포수평교고（ P＜0．05）；혈청TSGF함량교저（P＜0．05）；유효솔교고（P＜0．05）。결론중조혈관내피억소능구명현강저만기식관위교접부선암환자외주혈Treg수평화혈청TSGF함량，제고CD8＋T세포수평，제고치료적유효솔，대림상유지도의의。
Objective To analyse the effect of recombinant endostatin on Treg, CD8 +T cells, tumor specific growth factor (TSGF) in peripheral blood of patients with advanced esophageal gastric junction adenocarcinoma and clinical efficacy observation.Methods 52 patients who were diagnosed with acute cerebral infarction in our hospital were collected.All patients were randomly divided into experimental group and control group, 26 cases in each group.The control group was given OLF chemotherapy, the experimental group was treated with OLF chemotherapy regimen combined with recombinant endostatin.21 days was 1 cycle, a total of 4 cycles.After treatment, the levels of Treg, CD8 +T cells, serum TSGF and clinical efficacy were detected in all patients.ResuIts After treatment, compared with control group,the peripheral blood Treg was significantly lower in the experimental group (P<0.05); the peripheral blood CD8 +T cells level in the experimental group was significantly higher (P<0.05);the serum TSGF level in the experimental group was significantly lower ( P<0.05 ); the effective of patients in the experimental group was higher ( P<0.05 ) . ConcIusion Recombinant endostatin can significantly reduce the levels of Treg and serum TSGF in patients with advanced esophageal gastric junction adenocarcinoma, improve the level of CD8 +T cells, and improve the efficiency of treatment, have guiding significance to clinical.